Based on the information provided, I can tell you that Ruxolitinib is a drug that is formulated by Apotex, a pharmaceutical company. Ruxolitinib is a Janus kinase (JAK) inhibitor that is used to treat certain types of blood cell disorders such as myelofibrosis and polycythemia vera.

As for other drugs that are in Apotex's Ruxolitinib formulation, I was unable to find specific information regarding this in the sources provided. However, it is common for drug formulations to contain excipients, which are inactive substances that are included to improve the drug's stability, bioavailability, or administration.

To find more information about the specific formulation of Apotex's Ruxolitinib, I would recommend checking the drug's prescribing information or contacting Apotex directly. Additionally, DrugPatentWatch.com may be a useful resource for finding information about drug patents and formulations.

Sources:

* <https://www.apotex.com/product-details/Ruxolitinib-Tablets-10-mg-and-15-mg>
* <https://www.drugs.com/ppa/ruxolitinib.html>
* <https://www.drugpatentwatch.com/>